Differential Impact of Relative Dose-Intensity Reductions in Diffuse Large B-Cell Lymphoma Treated with R-CHOP21 or R-CHOP14.

Show simple item record

dc.contributor.author Gutierrez, A.
dc.contributor.author Bento, L.
dc.contributor.author Bautista, A.M.
dc.contributor.author Garcia, F.
dc.contributor.author Martinez-Serra, J.
dc.contributor.author Sanchez, B.
dc.contributor.author Martorell, C.
dc.contributor.author Gines, J.
dc.contributor.author Garcia, L.
dc.contributor.author Gimeno, E.
dc.contributor.author Ferraro, M.
dc.contributor.author Del Campo, R.
dc.contributor.author Bargay, J.
dc.contributor.author Perez, A.
dc.contributor.author Vercher, J.
dc.contributor.author Scaff, M.
dc.contributor.author Pacheco, A.
dc.contributor.author Ballester, C.
dc.contributor.author Garcia, F.
dc.contributor.author Ramos, R.
dc.contributor.author Salar, A.
dc.contributor.author Besalduch, J.
dc.date.accessioned 2019-09-24T06:27:55Z
dc.date.available 2019-09-24T06:27:55Z
dc.identifier.uri http://hdl.handle.net/11201/149932
dc.description.abstract DLBCL is an aggressive lymphoma treated with R-CHOP. Recently, attempts have been made to improve the outcome by increasing both dose-density and intensity but there have been no benefits in terms of survival. When treating malignancies RDI is important to consider but there is little published information on DLBCL. The purpose of this study was to analyze the differential prognostic impact of RDI in two cohorts of DLBCL patients treated with R-CHOP21 or R-CHOP14. From January 2001 to August 2013 we included DLBCL patients homogenously treated with R-CHOP21 or R-CHOP14, with or without radiotherapy, at University Hospital Son Espases, Hospital Son Llatzer of Palma and Hospital del Mar of Barcelona (N = 157). In order to avoid selection bias the patients were retrospectively identified from the Pathology Department and Pharmacy registries. Median follow-up was 68 months. There was no difference in the response or survival between the two cohorts. In the R-CHOP21 group, both a reduction higher than 15% in RDI (RR 7.41) and R-IPI (RR 2.99) were independently associated with OS. However, a reduction higher than 15% in RDI (RR 4.41) was only noted for PFS. In the R-CHOP14 group, NCCN-IPI (RR 7.09) and B-symptoms (RR 5.37) for OS; AA stage III-IV (RR 6.26) and bulky disease (RR 4.05) for PFS. There was a trend towards a higher rate of RDI reduction observed in the R-CHOP14 group but it only made an impact in the R-CHOP21 group. We conclude that R-CHOP21 and R-CHOP14 are equivalent regimens in terms of response and survival, but only if RDI reductions are avoided. For patients receiving R-CHOP21 we recommend using clinical and support measures in order to avoid RDI reductions.
dc.format application/pdf
dc.relation.isformatof Reproducció del document publicat a: https://doi.org/10.1371/journal.pone.0123978
dc.relation.ispartof Plos One, 2015, p. 1-11
dc.rights cc-by (c) Gutierrez, A. et al., 2015
dc.rights.uri http://creativecommons.org/licenses/by/3.0/es
dc.subject.classification 616 - Patologia. Medicina clínica. Oncologia
dc.subject.other 616 - Pathology. Clinical medicine
dc.title Differential Impact of Relative Dose-Intensity Reductions in Diffuse Large B-Cell Lymphoma Treated with R-CHOP21 or R-CHOP14.
dc.type info:eu-repo/semantics/article
dc.type info:eu-repo/semantics/publishedVersion
dc.date.updated 2019-09-24T06:27:56Z
dc.rights.accessRights info:eu-repo/semantics/openAccess
dc.identifier.doi https://doi.org/10.1371/journal.pone.0123978

Files in this item

The following license files are associated with this item:

This item appears in the following Collection(s)

Show simple item record

cc-by (c) Gutierrez, A. et al., 2015 Except where otherwise noted, this item's license is described as cc-by (c) Gutierrez, A. et al., 2015

Search Repository

Advanced Search


My Account